Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
Rhea-AI Summary
Biohaven (NYSE: BHVN) reported Q3 2025 results and strategic reprioritization on Nov 10, 2025. The company recorded a GAAP net loss of $173.4M ($1.64/share) and a non-GAAP adjusted net loss of $155.9M ($1.47/share). Cash, cash equivalents, marketable securities and restricted cash totaled $263.8M as of Sept 30, 2025. Biohaven initiated cost optimization to focus on three late-stage value-driving programs: opakalim (Kv7 activator for focal epilepsy and MDD), lead TRAP/MoDE degraders (BHV-1400 for IgAN, BHV-1300 for Graves' disease) and taldefgrobep alfa (myostatin-activin inhibitor for obesity and SMA).
Management expects ~60% reduction in annual direct R&D spend and milestone timing including top-line MDD results in 4Q 2025, focal epilepsy results in 1H 2026, and a Phase 2 obesity start in 4Q 2025.
Positive
- Expected ~60% reduction in annual direct R&D spend
- Cash and equivalents of $263.8M as of Sept 30, 2025
- Top-line MDD results for opakalim expected in 4Q 2025
- Focal epilepsy initial results for opakalim expected in 1H 2026
- Phase 2 obesity initiation for taldefgrobep alfa planned in 4Q 2025
Negative
- GAAP net loss $173.4M in Q3 2025 (vs $160.3M prior year)
- Other income swung to $3.8M expense in Q3 2025 from $17.8M income prior year
- Restructuring may pause, delay or halt non-priority programs
News Market Reaction – BHVN
On the day this news was published, BHVN declined 5.69%, reflecting a notable negative market reaction. Argus tracked a peak move of +12.9% during that session. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $56M from the company's valuation, bringing the market cap to $928M at that time.
Data tracked by StockTitan Argus on the day of publication.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "Biohaven remains energized and focused on our mission to advance innovative medicines to patients who are waiting every day for new treatments. Our pipeline consists of multiple novel approaches for unmet medical needs and has the potential to deliver paradigm shifting treatments for conditions such as epilepsy, autoimmune disease, obesity, depression and cancer. We are particularly excited about the continued progress across our key programs and clinical-stage assets including: MoDE™ and TRAP™ degrader programs, where our two lead assets, BHV-1300 and BHV-1400, show compelling evidence to change the treatment paradigm in immune-mediated diseases; opakalim, a novel Kv7 ion channel activator, for the treatment of epilepsy and depression; and taldefgrobep alfa, myostatin-activin targeting therapy for obesity and SMA."
Dr. Coric continued, "Our late-stage clinical programs are poised to transform their respective treatment paradigms, given their novel mechanistic foundations and the body of clinical and non-clinical data generated to date. Our redirected approach to 'right-sizing' innovation is an important step we have undertaken to ultimately drive growth and resources to the most critical areas of our business. With this thoughtful approach to rebalancing our portfolio, we believe Biohaven remains well-positioned to execute on our commitment to transforming the treatment landscape for patients with serious and underserved diseases and we remain unwaveringly committed to delivering on our promise to advance our programs for patients, families, and shareholders in the balance of the year and in the years ahead. We will also continue to provide updates on any progress determining a path forward in SCA."
Third Quarter 2025 and Recent Business Updates
-
Initiated strategic cost optimization efforts across portfolio to focus forward-looking spend on three value-driving, late-stage clinical programs that will prioritize resources:
- Opakalim, Kv7 ion channel activator, in pivotal studies for focal epilepsy and depression;
- Lead TRAP and MoDE extracellular degraders for IgA nephropathy (BHV-1400) and Graves' disease (BHV-1300);
- Taldefgrobep alfa, myostatin-activin pathway inhibitor, for obesity and spinal muscular atrophy.
-
Restructuring of business priorities and optimizing resource allocation may result in either pause, delay or halting of non-priority programs.
- The cost optimization efforts are expected to achieve an approximately
60% reduction in annual direct R&D spend (which excludes personnel and share-based compensation).
- The cost optimization efforts are expected to achieve an approximately
Expected Upcoming Milestones:
We believe Biohaven is well positioned to achieve significant, value-creating milestones in 2025 and 2026 across numerous programs:
Kv7 Activator (Opakalim):
- Deliver top-line results from Phase 2 study in major depressive disorder study in 4Q 2025.
- Continue two Phase 2/3 studies in focal epilepsy with initial top-line results expected in 1H 2026.
Lead TRAP and MoDE Extracellular Degraders (BHV-1400 and BHV-1300)
- Continue enrollment of patients with IgAN and Graves's disease in expanded Phase 1b and advance to pivotal studies in IgAN and Graves' disease.
Myostatin-Activin Pathway Inhibitor (Taldefgrobep alfa):
- Initiate Phase 2 clinical trial in obesity in 4Q 2025.Continue ongoing Health Authority interactions to discuss SMA registrational path in the US and
Europe .
Glutamate Modulator (VYGLXIA):
- We requested a Type A meeting with FDA as part of initiating an appeal process for the SCA CRL and plan to meet with the FDA to discuss potential next steps.
Capital Position:
Cash, cash equivalents, marketable securities and restricted cash as of September 30, 2025, totaled approximately
Third Quarter 2024 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share-based compensation costs, were
General and Administrative (G&A) Expenses: G&A expenses, including non-cash share-based compensation costs, were
Other (Expense) Income, Net: Other (expense) income, net was other expense, net of
Net Loss: Biohaven reported a net loss for the three months ended September 30, 2025 of
Non-GAAP Financial Measures
This press release includes financial results prepared in accordance with accounting principles generally accepted in
In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this news release.
About Biohaven
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. The company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; MoDE™ and TRAP™ extracellular protein degradation for immunological diseases; and myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected timing and amounts of funding under the NPA. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates and regarding reduction in annual direct R&D spend, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable
|
BIOHAVEN LTD. |
||||||||||||||||
|
CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||
|
(Amounts in thousands, except share and per share amounts) |
||||||||||||||||
|
(Unaudited) |
||||||||||||||||
|
|
||||||||||||||||
|
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
||||||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||
|
Research and development |
|
$ 141,169 |
|
$ 157,607 |
|
$ 513,120 |
|
$ 628,398 |
||||||||
|
General and administrative |
|
28,213 |
|
20,561 |
|
89,524 |
|
66,782 |
||||||||
|
Total operating expenses |
|
169,382 |
|
178,168 |
|
602,644 |
|
695,180 |
||||||||
|
Loss from operations |
|
(169,382) |
|
(178,168) |
|
(602,644) |
|
(695,180) |
||||||||
|
Other income, net |
|
(3,840) |
|
17,805 |
|
10,468 |
|
36,288 |
||||||||
|
Loss before provision (benefit) for income taxes |
|
(173,222) |
|
(160,363) |
|
(592,176) |
|
(658,892) |
||||||||
|
Provision (benefit) for income taxes |
|
221 |
|
(59) |
|
1,091 |
|
687 |
||||||||
|
Net loss |
|
$ (173,443) |
|
$ (160,304) |
|
$ (593,267) |
|
$ (659,579) |
||||||||
|
Net loss per share — basic and diluted |
|
$ (1.64) |
|
$ (1.70) |
|
$ (5.74) |
|
$ (7.50) |
||||||||
|
Weighted average common shares outstanding— basic and diluted |
|
105,815,038 |
|
94,372,159 |
|
103,391,267 |
|
87,936,923 |
||||||||
|
BIOHAVEN LTD. |
||||||||
|
CONSOLIDATED BALANCE SHEETS |
||||||||
|
(Amounts in thousands, except share amounts) |
||||||||
|
|
||||||||
|
|
|
September 30, 2025 |
|
December 31, 2024 |
||||
|
|
|
(Unaudited) |
|
|
||||
|
Assets |
|
|
|
|
||||
|
Current assets: |
|
|
|
|
||||
|
Cash and cash equivalents |
|
$ 184,847 |
|
$ 99,134 |
||||
|
Marketable securities |
|
75,370 |
|
386,857 |
||||
|
Prepaid expenses |
|
54,983 |
|
49,376 |
||||
|
Other current assets |
|
8,415 |
|
3,105 |
||||
|
Total current assets |
|
323,615 |
|
538,472 |
||||
|
Property and equipment, net |
|
17,521 |
|
17,320 |
||||
|
Intangible assets |
|
18,400 |
|
18,400 |
||||
|
Goodwill |
|
1,390 |
|
1,390 |
||||
|
Other non-current assets |
|
48,197 |
|
39,525 |
||||
|
Total assets |
|
$ 409,123 |
|
$ 615,107 |
||||
|
Liabilities and Shareholders' Equity |
|
|
|
|
||||
|
Current liabilities: |
|
|
|
|
||||
|
Accounts payable |
|
$ 17,491 |
|
$ 18,029 |
||||
|
Accrued expenses and other current liabilities |
|
73,522 |
|
51,487 |
||||
|
Forward contract and derivative liability |
|
22,010 |
|
84,710 |
||||
|
Total current liabilities |
|
113,023 |
|
154,226 |
||||
|
Non-current operating lease liability |
|
40,394 |
|
32,782 |
||||
|
Notes payable |
|
268,270 |
|
— |
||||
|
Other non-current liabilities |
|
4,596 |
|
4,663 |
||||
|
Total liabilities |
|
426,283 |
|
191,671 |
||||
|
Shareholders' Equity: |
|
|
|
|
||||
|
Preferred shares, no par value; 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2025 and December 31, 2024 |
|
— |
|
— |
||||
|
Common shares, no par value; 200,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 105,803,655 and 101,221,989 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively |
|
1,743,740 |
|
1,656,702 |
||||
|
Additional paid-in capital |
|
178,045 |
|
112,369 |
||||
|
Accumulated deficit |
|
(1,938,981) |
|
(1,345,714) |
||||
|
Accumulated other comprehensive (loss) income |
|
36 |
|
79 |
||||
|
Total shareholders' equity |
|
(17,160) |
|
423,436 |
||||
|
Total liabilities and shareholders' equity |
|
$ 409,123 |
|
$ 615,107 |
||||
|
BIOHAVEN LTD. |
||||||||||||||||
|
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES |
||||||||||||||||
|
(Amounts in thousands, except share and per share amounts) |
||||||||||||||||
|
(Unaudited) |
||||||||||||||||
|
|
||||||||||||||||
|
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
||||||||
|
Reconciliation of GAAP to Non-GAAP adjusted net loss: |
|
|
|
|
|
|
|
|
||||||||
|
GAAP net loss |
|
$ (173,443) |
|
$ (160,304) |
|
$ (593,267) |
|
$ (659,579) |
||||||||
|
Add: non-cash share-based compensation expense |
|
21,535 |
|
12,160 |
|
95,409 |
|
59,269 |
||||||||
|
Add: (gain) loss from change in fair value of derivatives |
|
(3,960) |
|
(15,990) |
|
8,800 |
|
(17,030) |
||||||||
|
Non-GAAP adjusted net loss |
|
$ (155,868) |
|
$ (164,134) |
|
$ (489,058) |
|
$ (617,340) |
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Reconciliation of GAAP to Non-GAAP adjusted net loss per share — basic and diluted: |
|
|
|
|
||||||||||||
|
GAAP net loss per share — basic and diluted |
|
$ (1.64) |
|
$ (1.70) |
|
$ (5.74) |
|
$ (7.50) |
||||||||
|
Add: non-cash share-based compensation expense |
|
0.21 |
|
0.13 |
|
0.92 |
|
0.67 |
||||||||
|
Add: (gain) loss from change in fair value of derivatives |
|
(0.04) |
|
(0.17) |
|
0.09 |
|
(0.19) |
||||||||
|
Non-GAAP adjusted net loss per share — basic and diluted |
|
$ (1.47) |
|
$ (1.74) |
|
$ (4.73) |
|
$ (7.02) |
||||||||
VYGLXIA is a registered trademark, and MoDE and TRAP are trademarks, of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-reports-third-quarter-2025-financial-results-and-recent-business-developments-302609810.html
SOURCE Biohaven Ltd.
FAQ
What net loss did Biohaven (BHVN) report for Q3 2025?
How much cash did Biohaven (BHVN) have at Sept 30, 2025?
What R&D cost savings did Biohaven (BHVN) announce on Nov 10, 2025?
When will Biohaven (BHVN) report top-line results for opakalim in major depressive disorder?
When are initial focal epilepsy results for opakalim expected for Biohaven (BHVN)?
What development milestones did Biohaven (BHVN) set for BHV-1400 and BHV-1300?
Could Biohaven (BHVN) stop any programs after the restructuring?
